Stockscreener 앱 받기
119.21
0.83%
-1.00
시간 외 거래:
119.62
0.41
+0.34%
전일 마감가:
$120.21
열려 있는:
$121.85
하루 거래량:
223.30K
Relative Volume:
1.19
시가총액:
$798.60M
수익:
-
순이익/손실:
$-14.99M
주가수익비율:
-57.69
EPS:
-2.0665
순현금흐름:
$-10.01M
1주 성능:
+10.02%
1개월 성능:
+25.19%
6개월 성능:
+106.42%
1년 성능:
+197.28%
1일 변동 폭
$118.04
$124.42
1주일 범위
$104.75
$124.82
52주 변동 폭
$29.18
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
119.21 | 739.11M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Morgan Stanley | Overweight |
| 2025-11-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 개시 | Leerink Partners | Outperform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monopar Therapeutics Inc (MNPR) Institutional Confidence - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MNPR|Monopar Therapeutics Inc|Price:110.450|Chg%:+0.580 - TradingKey
Monopar Therapeutics Inc (MNPR) Cash Flow - TradingKey
BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup - TipRanks
MONOPAR THERAPEUTICS INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105 - webull.com
Monopar Therapeutics Inc (MNPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why is Monopar Therapeutics stock down 7.6% today? - Traders Union
Monopar Therapeutics Inc. (MNPR) stock price, news, quote and history - Yahoo Finance UK
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115 - Moomoo
H.C. Wainwright raises Monopar stock price target to $125 on NDA filing - Investing.com
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
MNPR Maintained by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Monopar Therapeutics (MNPR) Proxy Filing Summary - Quartr
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125 - TipRanks
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease - Moomoo
Monopar Begins Rolling FDA NDA Submission for ALXN1840 - TipRanks
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease - The Manila Times
ALXN1840 Could Be First U.S. Wilson Therapy With Novel Mechanism in Decades - Stock Titan
Can leadership appointments spark further gains for Monopar Therapeutics stock? - Traders Union
Monopar adds commercial leaders ahead of drug filing By Investing.com - Investing.com Nigeria
Monopar Therapeutics stock slips below $105.4 support as weak price closes pressure momentum - Traders Union
MNPR stock draws attention as Monopar Therapeutics advances pipeline and reports recent financing me - Ad-hoc-news.de
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team - The Manila Times
Monopar adds commercial leaders ahead of drug filing - Investing.com
Former KalVista chief joins Monopar board as Wilson drug prep expands - Stock Titan
MNPR stock trades quietly as Monopar Therapeutics advances cancer pipeline - Ad-hoc-news.de
Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy) - Seeking Alpha
Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com - Investing.com South Africa
Monopar Therapeutics stock trades near $98.20–$111.48 range as buyer strength dominates session - Traders Union
Will Monopar Therapeutics stock regain momentum as buyers support the ongoing rally? - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates Significantly Despite Revenue AbsenceROA Comparison - dars.gov.et
Price to sales forward of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock drops almost 4% after earnings beat followed by downgrade to 'sell' - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates by 46% as Pipeline AdvancesEarnings Acceleration Picks - dars.gov.et
(MNPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
Monopar Therapeutics shares gain about 9.5% after immediate support holds above $100.45 - Traders Union
What's behind Monopar Therapeutics's latest 11.6% stock surge? - Traders Union
Monopar Therapeutics (MNPR) Surges 8.98% as Buyers Test Key Resistance ZoneSign of Weakness - dars.gov.et
Form 144 Monopar Therapeutics Inc. For: 7 July By Investing.com - Investing.com Nigeria
[144] Monopar Therapeutics SEC Filing - Stock Titan
MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline. - ad-hoc-news.de
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monopar Therapeutics Inc 주식 (MNPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Vu Quan Anh | Chief Financial Officer |
Dec 26 '25 |
Buy |
69.95 |
1,500 |
104,925 |
1,500 |
1.84%
0.86%
자본화:
|
볼륨(24시간):